Spironolactone or placebo in adults with alcohol use disorder: a Phase 1b safety study
Understand this study
Who could participate?
Listed age limits: 21 years to 99 years.
What will I do during this study?
The protocol describes four separate seven-day clinic stays. Participants take spironolactone capsules during three stays and placebo (an inactive comparison treatment) capsules during one stay. The protocol also includes drinking alcohol under observation and measuring breath and blood alcohol levels.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 20
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 99 Years
- Official registry ID
- NCT05807139
- Official title
Show the full official title
Spironolactone in Alcohol Use Disorder (SAUD): A Double-Blind, Placebo-Controlled, Ascending Dose, Phase 1b Study
Recruitment & locations
Baltimore
Interested in joining this study?
Questions about this study
What will I need to do?
You will take study medication.
Who is behind this study?
The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.
Does this study involve medication?
Yes. The study involves medication, including Spironolactone.
Who can participate?
Listed age limits: 21 years to 99 years.
Is this study still recruiting?
The registry lists this study as recruiting.
